Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 269

1.

Diagnostic and prognostic values of PBMC proteins in amyotrophic lateral sclerosis.

Luotti S, Pasetto L, Porcu L, Torri V, Elezgarai SR, Pantalone S, Filareti M, Corbo M, Lunetta C, Mora G, Bonetto V.

Neurobiol Dis. 2020 Feb 19:104815. doi: 10.1016/j.nbd.2020.104815. [Epub ahead of print]

PMID:
32087285
2.

Real-world guideline application in the management of pancreatic cancer patients: the Italian GARIBALDI study.

Reni M, Bergamo F, Cavanna L, Spada M, Ghidini M, Giommoni E, Maiello E, Artioli F, Cardellino G, Torri V, Cinquini M, Giugliano V, Pinto C.

Ann Oncol. 2019 Jul;30 Suppl 4:iv36. doi: 10.1093/annonc/mdz155.133. Epub 2019 Dec 4. No abstract available.

PMID:
32085132
3.

Author Correction: Visual field loss and vision-related quality of life in the Italian Primary Open Angle Glaucoma Study.

Rulli E, Quaranta L, Riva I, Poli D, Hollander L, Galli F, Katsanos A, Oddone F, Torri V, Weinreb RN; Italian Study Group on QoL in Glaucoma.

Sci Rep. 2020 Feb 21;10(1):3189. doi: 10.1038/s41598-020-59555-6.

PMID:
32081876
4.

Correction to: Standard (8 weeks) vs long (12 weeks) timing to minimally-invasive surgery after NeoAdjuvant Chemoradiotherapy for rectal cancer: a multicenter randomized controlled parallel group trial (TiMiSNAR).

Monsellato I, Alongi F, Bertocchi E, Gori S, Ruffo G, Cassinotti E, Baldari L, Boni L, Pernazza G, Pulighe F, De Nisco C, Perinotti R, Morpurgo E, Contardo T, Mammano E, Elmore U, Delpini R, Rosati R, Perna F, Coratti A, Menegatti B, Gentilli S, Baroffio P, Buccianti P, Balestri R, Ceccarelli C, Torri V, Cavaliere D, Solaini L, Ercolani G, Traverso E, Fusco V, Rossi M, Priora F, Numico G, Franzone P, Orecchia S.

BMC Cancer. 2020 Feb 17;20(1):128. doi: 10.1186/s12885-020-6632-y.

5.

Turn off pain: What has changed 4 years later?

Benini F, Terrenato I, Lazzarin P, Borrometi F, Jankovic M, Torri V, Giacomelli L, Gentili M.

Acta Paediatr. 2020 Jan 29. doi: 10.1111/apa.15199. [Epub ahead of print] No abstract available.

PMID:
31994753
6.

Assessment of assumptions of statistical analysis methods in randomised clinical trials: the what and how.

Nørskov AK, Lange T, Nielsen EE, Gluud C, Winkel P, Beyersmann J, de Uña-Álvarez J, Torri V, Billot L, Putter H, Wetterslev J, Thabane L, Jakobsen JC.

BMJ Evid Based Med. 2020 Jan 27. pii: bmjebm-2019-111268. doi: 10.1136/bmjebm-2019-111268. [Epub ahead of print]

PMID:
31988195
7.

Early progression of disease predicts shorter survival in MALT lymphoma patients receiving systemic treatment.

Conconi A, Thieblemont C, Cascione L, Torri V, Kiesewetter B, Margiotta Casaluci G, Gaidano G, Raderer M, Cavalli F, Lopez Guillermo A, Johnson PW, Zucca E.

Haematologica. 2020 Jan 2. pii: haematol.2019.237990. doi: 10.3324/haematol.2019.237990. [Epub ahead of print]

8.

Standard (8 weeks) vs long (12 weeks) timing to minimally-invasive surgery after NeoAdjuvant Chemoradiotherapy for rectal cancer: a multicenter randomized controlled parallel group trial (TiMiSNAR).

Monsellato I, Alongi F, Bertocchi E, Gori S, Ruffo G, Cassinotti E, Baldari L, Boni L, Pernazza G, Pulighe F, De Nisco C, Perinotti R, Morpurgo E, Contardo T, Mammano E, Elmore U, Delpini R, Rosati R, Perna F, Coratti A, Menegatti B, Gentilli S, Baroffio P, Buccianti P, Balestri R, Ceccarelli C, Torri V, Cavaliere D, Solaini L, Ercolani G, Traverso E, Fusco V, Rossi M, Priora F, Numico G, Franzone P, Orecchia S.

BMC Cancer. 2019 Dec 16;19(1):1215. doi: 10.1186/s12885-019-6271-3. Erratum in: BMC Cancer. 2020 Feb 17;20(1):128.

9.

EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort.

Prelaj A, Ferrara R, Rebuzzi SE, Proto C, Signorelli D, Galli G, De Toma A, Randon G, Pagani F, Viscardi G, Brambilla M, Trevisan B, Ganzinelli M, Martinetti A, Gallucci R, Di Mauro RM, Molino G, Zilembo N, Torri V, de Braud FM, Garassino MC, Lo Russo G.

Cancers (Basel). 2019 Dec 5;11(12). pii: E1954. doi: 10.3390/cancers11121954.

10.

Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer.

Colombo N, Zaccarelli E, Baldoni A, Frezzini S, Scambia G, Palluzzi E, Tognon G, Lissoni AA, Rubino D, Ferrero A, Farina G, Negri E, Pesenti Gritti A, Galli F, Biagioli E, Rulli E, Poli D, Gerardi C, Torri V, Fossati R, D'Incalci M.

Br J Cancer. 2019 Oct;121(9):744-750. doi: 10.1038/s41416-019-0584-5. Epub 2019 Sep 20.

PMID:
31537908
11.

Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study.

Cazzaniga ME, Pinotti G, Montagna E, Amoroso D, Berardi R, Butera A, Cagossi K, Cavanna L, Ciccarese M, Cinieri S, Cretella E, De Conciliis E, Febbraro A, Ferraù F, Ferzi A, Fiorentini G, Fontana A, Gambaro AR, Garrone O, Gebbia V, Generali D, Gianni L, Giovanardi F, Grassadonia A, Leonardi V, Marchetti P, Melegari E, Musolino A, Nicolini M, Putzu C, Riccardi F, Santini D, Saracchini S, Sarobba MG, Schintu MG, Scognamiglio G, Spadaro P, Taverniti C, Toniolo D, Tralongo P, Turletti A, Valenza R, Valerio MR, Vici P, Clivio L, Torri V; VICTOR Study Group.

Breast. 2019 Dec;48:7-16. doi: 10.1016/j.breast.2019.07.006. Epub 2019 Aug 22.

PMID:
31470257
12.

Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study.

Di Cosimo S, La Verde N, Moretti A, Cazzaniga ME, Generali D, Bianchi GV, Mariani L, Torri V, Crippa F, Paolini B, Scaperrotta G, De Santis MC, Di Nicola M, Apolone G, Gulino A, Tripodo C, Colombo MP, Folli S, de Braud F.

PLoS One. 2019 Aug 7;14(8):e0220644. doi: 10.1371/journal.pone.0220644. eCollection 2019.

13.

The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study.

Di Cosimo S, Triulzi T, Pizzamiglio S, De Cecco L, de Azambuja E, Fumagalli D, Putzai L, Harbeck N, Izquierdo M, Peña L, Daidone MG, Huober J, Gori S, Cinieri S, Torri V, Baselga J, Piccart M, de Braud FG, Apolone G, Verderio P, Tagliabue E.

Eur J Cancer. 2019 Sep;118:1-9. doi: 10.1016/j.ejca.2019.06.001. Epub 2019 Jul 5.

14.

RE: Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis.

Di Cosimo S, Torri V, Porcu L.

J Natl Cancer Inst. 2019 Nov 1;111(11):1232-1233. doi: 10.1093/jnci/djz092. No abstract available.

PMID:
31187132
15.

Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial.

Platania M, Pasini F, Porcu L, Boeri M, Verderame F, Modena Y, Del Conte A, Nichetti F, Garassino MC, Martinetti A, Sottotetti E, Cavanna L, Vattemi E, Pozzessere D, Bertolini A, Irtelli L, Verri C, Sozzi G, Proto C, Pastorino U, Torri V, Fraccon AP, Spinnato F, Signorelli D, Lo Russo G, Tuzi A, Gallucci R, Cinieri S, Mencoboni M, Antonelli P, Giacomelli L, de Braud F.

Lung Cancer. 2019 Jun;132:17-23. doi: 10.1016/j.lungcan.2019.04.001. Epub 2019 Apr 3.

PMID:
31097088
16.

Gadoxetate Disodium-Enhanced MR Cholangiography for Evaluation of Biliary-Enteric Anastomoses: Added Value Beyond Conventional T2-Weighted Images.

Boraschi P, Donati F, Pacciardi F, Cervelli R, Gigoni R, Porcu L, Torri V.

AJR Am J Roentgenol. 2019 Sep;213(3):W123-W133. doi: 10.2214/AJR.18.20626. Epub 2019 May 7.

PMID:
31063422
17.

A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205.

Hotte SJ, Chi KN, Joshua AM, Tu D, Macfarlane RJ, Gregg RW, Ruether JD, Basappa NS, Finch D, Salim M, Winquist EW, Torri V, North S, Kollmannsberger C, Ellard SL, Eigl BJ, Tinker A, Allan AL, Beja K, Annala M, Powers J, Wyatt AW, Seymour L; Canadian Cancer Trials Group (formerly NCIC Clinical Trials Group).

Clin Genitourin Cancer. 2019 Jun;17(3):201-208.e1. doi: 10.1016/j.clgc.2019.03.005. Epub 2019 Mar 15.

PMID:
31056399
18.

Prognostic nutritional index as a prognostic marker in glioblastoma: Data from a cohort of 282 Italian patients.

Rigamonti A, Imbesi F, Silvani A, Lamperti E, Agostoni E, Porcu L, De Simone I, Torri V, Ciusani E, Bonato C, Salmaggi A.

J Neurol Sci. 2019 May 15;400:175-179. doi: 10.1016/j.jns.2019.04.002. Epub 2019 Apr 3.

PMID:
30974322
19.

Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors.

Fucà G, Galli G, Poggi M, Lo Russo G, Proto C, Imbimbo M, Ferrara R, Zilembo N, Ganzinelli M, Sica A, Torri V, Colombo MP, Vernieri C, Balsari A, de Braud F, Garassino MC, Signorelli D.

ESMO Open. 2019 Feb 27;4(1):e000457. doi: 10.1136/esmoopen-2018-000457. eCollection 2019.

20.

Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out.

Proto C, Ferrara R, Signorelli D, Lo Russo G, Galli G, Imbimbo M, Prelaj A, Zilembo N, Ganzinelli M, Pallavicini LM, De Simone I, Colombo MP, Sica A, Torri V, Garassino MC.

Cancer Treat Rev. 2019 May;75:39-51. doi: 10.1016/j.ctrv.2019.03.004. Epub 2019 Mar 28. Review.

Supplemental Content

Loading ...
Support Center